Anker, Stefan Dietmar

[["dc.bibliographiccitation.firstpage","325"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","334"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Rozentryt, Piotr"],["dc.contributor.author","Niedziela, Jacek T."],["dc.contributor.author","Hudzik, Bartosz"],["dc.contributor.author","Lekston, Andrzej"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Jankowska, Ewa A."],["dc.contributor.author","Nowak, Jolanta"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Partyka, Robert"],["dc.contributor.author","Rywik, Tomasz"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Poloński, Lech"],["dc.date.accessioned","2019-07-09T11:42:02Z"],["dc.date.available","2019-07-09T11:42:02Z"],["dc.date.issued","2015"],["dc.description.abstract","Background A higher serum phosphate level is associated with worse outcome. Energy-demanding intracellular transport of phosphate is needed to secure anion bioavailability. In heart failure (HF), energy starvation may modify intracellular and serum levels of phosphate. We analysed determinants of serum phosphates in HF and assessed if catabolic/anabolic balance (CAB) was associated with elevation of serum phosphate. Methods We retrospectively reviewed data from 1029 stable patients with HF and have calculated negative (loss) and positive (gain) components of weight change from the onset of HF till index date. The algebraic sum of these components was taken as CAB. The univariate and multivariable predictors of serum phosphorus were calculated. In quintiles of CAB, we have estimated odds ratios for serum phosphorus above levels previously identified to increase risk of mortality. As a reference, we have selected a CAB quintile with similar loss and gain. Results Apart from sex, age, and kidney function, we identified serum sodium, N-terminal fragment of pro-brain-type natriuretic peptide, and CAB as independent predictors of serum phosphorus. The odds for serum phosphorus above thresholds found in literature to increase risk were highest in more catabolic patients. In most catabolic quintile relative to neutral balance, the odds across selected phosphorus thresholds rose, gradually peaking at 1.30 mmol/L with a value of 3.29 (95% confidence interval: 2.00–5.40, P < 0.0001) in an unadjusted analysis and 2.55 (95% confidence interval: 1.38–2.72, P = 0.002) in a fully adjusted model. Conclusions Metabolic status is an independent determinant of serum phosphorus in HF. Higher catabolism is associated with serum phosphorus above mortality risk-increasing thresholds."],["dc.identifier.doi","10.1002/jcsm.12026"],["dc.identifier.pmid","26672973"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12707"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58571"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/241558/EU//SICA-HF"],["dc.relation.euproject","SICA-HF"],["dc.relation.issn","2190-6009"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","965"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","973"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Markousis‐Mavrogenis, George"],["dc.contributor.author","Tromp, Jasper"],["dc.contributor.author","Ouwerkerk, Wouter"],["dc.contributor.author","Devalaraja, Matt"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Cleland, John G."],["dc.contributor.author","Dickstein, Kenneth"],["dc.contributor.author","Filippatos, Gerasimos S."],["dc.contributor.author","Harst, Pim"],["dc.contributor.author","Lang, Chim C."],["dc.contributor.author","Metra, Marco"],["dc.contributor.author","Ng, Leong L."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Samani, Nilesh J"],["dc.contributor.author","Zannad, Faiez"],["dc.contributor.author","Zwinderman, Aeilko H."],["dc.contributor.author","Hillege, Hans L."],["dc.contributor.author","Veldhuisen, Dirk J."],["dc.contributor.author","Kakkar, Rahul"],["dc.contributor.author","Voors, Adriaan A."],["dc.contributor.author","Meer, Peter"],["dc.date.accessioned","2020-12-10T14:06:17Z"],["dc.date.available","2020-12-10T14:06:17Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/ejhf.1482"],["dc.identifier.eissn","1879-0844"],["dc.identifier.issn","1388-9842"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16656"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69840"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.title","The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","621"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","628"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Okonko, Darlington O."],["dc.contributor.author","Jouhra, Fadi"],["dc.contributor.author","Abu‐Own, Huda"],["dc.contributor.author","Filippatos, Gerasimos"],["dc.contributor.author","Colet, Josep Comin"],["dc.contributor.author","Suki, Chainey"],["dc.contributor.author","Mori, Claudio"],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2020-12-10T14:06:11Z"],["dc.date.available","2020-12-10T14:06:11Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/ehf2.12462"],["dc.identifier.eissn","2055-5822"],["dc.identifier.issn","2055-5822"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16562"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69807"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR‐HF substudy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1050"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","European journal of heart failure"],["dc.bibliographiccitation.lastpage","1056"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Kosiborod, Mikhail"],["dc.contributor.author","Zannad, Faiez"],["dc.contributor.author","Piña, Ileana L."],["dc.contributor.author","McCullough, Peter A."],["dc.contributor.author","Filippatos, Gerasimos"],["dc.contributor.author","van der Meer, Peter"],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Rasmussen, Henrik S."],["dc.contributor.author","Lavin, Philip T."],["dc.contributor.author","Singh, Bhupinder"],["dc.contributor.author","Yang, Alex"],["dc.contributor.author","Deedwania, Prakash"],["dc.date.accessioned","2019-07-09T11:41:57Z"],["dc.date.available","2019-07-09T11:41:57Z"],["dc.date.issued","2015-10-01"],["dc.description.abstract","AIMS: Hyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS-9) is a selective potassium ion trap, whose mechanism of action may allow for potassium binding in the upper gastrointestinal tract as early as the duodenum following oral administration. ZS-9 previously demonstrated the ability to reduce elevated potassium levels into the normal range, with a median time of normalization of 2.2 h and sustain normal potassium levels for 28 days in HARMONIZE-a Phase 3, double-blind, randomized, placebo-controlled trial. In the present study we evaluated management of serum potassium with daily ZS-9 over 28 days in heart failure patients from HARMONIZE, including those receiving RAASi therapies. METHODS AND RESULTS: Heart failure patients with evidence of hyperkalaemia (serum potassium ≥5.1 mmol/L, n = 94) were treated with open-label ZS-9 for 48 h. Patients (n = 87; 60 receiving RAASi) who achieved normokalaemia (potassium 3.5-5.0 mmol/L) were randomized to daily ZS-9 (5, 10, or 15 g) or placebo for 28 days. Mean potassium and proportion of patients maintaining normokalaemia during days 8-29 post-randomization were evaluated. Despite RAASi doses being kept constant, patients on 5 g, 10 g, and 15 g ZS-9 maintained a lower potassium level (4.7 mmol/L, 4.5 mmol/L, and 4.4 mmol/L, respectively) than the placebo group (5.2 mmol/L; P<0.01 vs. each ZS-9 group); greater proportions of ZS-9 patients (83%, 89%, and 92%, respectively) maintained normokalaemia than placebo (40%; P < 0.01 vs. each ZS-9 group). The safety profile was consistent with previously reported overall study population. CONCLUSION: Compared with placebo, all three ZS-9 doses lowered potassium and effectively maintained normokalaemia for 28 days in heart failure patients without adjusting concomitant RAASi, while maintaining a safety profile consistent with the overall study population."],["dc.identifier.doi","10.1002/ejhf.300"],["dc.identifier.pmid","26011677"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12624"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58558"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1879-0844"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1374"],["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.lastpage","1383"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","van Veldhuisen, Dirk J."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","van der Meer, Peter"],["dc.contributor.author","Metra, Marco"],["dc.contributor.author","Böhm, Michael"],["dc.contributor.author","Doletsky, Artem"],["dc.contributor.author","Voors, Adriaan A."],["dc.contributor.author","Macdougall, Iain C."],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Roubert, Bernard"],["dc.contributor.author","Zakin, Lorraine"],["dc.contributor.author","Cohen-Solal, Alain"],["dc.date.accessioned","2020-12-10T18:38:02Z"],["dc.date.available","2020-12-10T18:38:02Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1161/CIRCULATIONAHA.117.027497"],["dc.identifier.eissn","1524-4539"],["dc.identifier.issn","0009-7322"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16999"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77169"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","932"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","942"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Abraham, William T."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Brueckmann, Martina"],["dc.contributor.author","Zeller, Cordula"],["dc.contributor.author","Macesic, Hemani"],["dc.contributor.author","Peil, Barbara"],["dc.contributor.author","Brun, Michèle"],["dc.contributor.author","Ustyugova, Anastasia"],["dc.contributor.author","Jamal, Waheed"],["dc.contributor.author","Salsali, Afshin"],["dc.contributor.author","Lindenfeld, JoAnn"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Abraham, William"],["dc.contributor.author","Anker, Stefan"],["dc.contributor.author","Welty, Francine"],["dc.contributor.author","Clayton, Tim"],["dc.contributor.author","Greenberg, Barry"],["dc.contributor.author","Konstam, Marvin"],["dc.contributor.author","Lees, Kennedy"],["dc.contributor.author","Palmer, Mike"],["dc.contributor.author","Parhofer, Klaus"],["dc.contributor.author","Pedersen, Terje"],["dc.contributor.author","Carson, Peter"],["dc.contributor.author","Freston, James"],["dc.contributor.author","Kaplowitz, Neil"],["dc.contributor.author","Lewis, James"],["dc.contributor.author","Mann, Johannes"],["dc.contributor.author","Petrie, John"],["dc.contributor.author","Agostoni, Piergiuseppe"],["dc.contributor.author","Butler, Javed"],["dc.contributor.author","Desai, Akshay"],["dc.contributor.author","Filippatos, Gerasimos"],["dc.contributor.author","Howlett, Jonathan"],["dc.contributor.author","Wranicz, Jerzy"],["dc.contributor.author","Mas, Josep Redón"],["dc.contributor.author","Cardoso, José Silva"],["dc.contributor.author","Störk, Stefan"],["dc.date.accessioned","2020-12-10T14:06:17Z"],["dc.date.available","2020-12-10T14:06:17Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/ejhf.1486"],["dc.identifier.eissn","1879-0844"],["dc.identifier.issn","1388-9842"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16728"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69841"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1147"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.bibliographiccitation.lastpage","1155"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Nauta, Jan F."],["dc.contributor.author","Hummel, Yoran M."],["dc.contributor.author","Tromp, Jasper"],["dc.contributor.author","Ouwerkerk, Wouter"],["dc.contributor.author","van der Meer, Peter"],["dc.contributor.author","Jin, Xuanyi"],["dc.contributor.author","Lam, Carolyn S.P."],["dc.contributor.author","Bax, Jeroen J."],["dc.contributor.author","Metra, Marco"],["dc.contributor.author","Samani, Nilesh J."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Dickstein, Kenneth"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Lang, Chim C."],["dc.contributor.author","Ng, Leong L."],["dc.contributor.author","Zannad, Faiez"],["dc.contributor.author","Filippatos, Gerasimos S."],["dc.contributor.author","van Veldhuisen, Dirk J."],["dc.contributor.author","van Melle, Joost P."],["dc.contributor.author","Voors, Adriaan A."],["dc.date.accessioned","2020-12-10T14:06:18Z"],["dc.date.available","2020-12-10T14:06:18Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/ejhf.1632"],["dc.identifier.eissn","1879-0844"],["dc.identifier.issn","1388-9842"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16849"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69848"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Clinical Research in Cardiology"],["dc.bibliographiccitation.lastpage","9"],["dc.contributor.author","Mordi, Ify R."],["dc.contributor.author","Santema, Bernadet T."],["dc.contributor.author","Kloosterman, Mariëlle"],["dc.contributor.author","Choy, Anna-Maria"],["dc.contributor.author","Rienstra, Michiel"],["dc.contributor.author","van Gelder, Isabelle"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Cleland, John G."],["dc.contributor.author","Dickstein, Kenneth"],["dc.contributor.author","Filippatos, Gerasimos"],["dc.contributor.author","van der Harst, Pim"],["dc.contributor.author","Hillege, Hans L."],["dc.contributor.author","Metra, Marco"],["dc.contributor.author","Ng, Leong L."],["dc.contributor.author","Ouwerkerk, Wouter"],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Samani, Nilesh J."],["dc.contributor.author","van Veldhuisen, Dirk J."],["dc.contributor.author","Zwinderman, Aeilko H."],["dc.contributor.author","Zannad, Faiez"],["dc.contributor.author","Voors, Adriaan A."],["dc.contributor.author","Lang, Chim C."],["dc.date.accessioned","2019-07-09T11:51:01Z"],["dc.date.available","2019-07-09T11:51:01Z"],["dc.date.issued","2019"],["dc.description.abstract","BACKGROUND: In patients with heart failure with reduced ejection fraction (HFrEF) on sub-optimal doses of beta-blockers, it is conceivable that changes in heart rate following treatment intensification might be important regardless of underlying heart rhythm. We aimed to compare the prognostic significance of both achieved heart rate and change in heart rate following beta-blocker uptitration in patients with HFrEF either in sinus rhythm (SR) or atrial fibrillation (AF). METHODS: We performed a post hoc analysis of the BIOSTAT-CHF study. We evaluated 1548 patients with HFrEF (mean age 67 years, 35% AF). Median follow-up was 21 months. Patients were evaluated at baseline and at 9 months. The combined primary outcome was all-cause mortality and heart failure hospitalisation stratified by heart rhythm and heart rate at baseline. RESULTS: Despite similar changes in heart rate and beta-blocker dose, a decrease in heart rate at 9 months was associated with reduced incidence of the primary outcome in both SR and AF patients [HR per 10 bpm decrease-SR: 0.83 (0.75-0.91), p < 0.001; AF: 0.89 (0.81-0.98), p = 0.018], whereas the relationship was less strong for achieved heart rate in AF [HR per 10 bpm higher-SR: 1.26 (1.10-1.46), p = 0.001; AF: 1.08 (0.94-1.23), p = 0.18]. Achieved heart rate at 9 months was only prognostically significant in AF patients with high baseline heart rates (p for interaction 0.017 vs. low). CONCLUSIONS: Following beta-blocker uptitration, both achieved and change in heart rate were prognostically significant regardless of starting heart rate in SR, however, they were only significant in AF patients with high baseline heart rate."],["dc.identifier.doi","10.1007/s00392-018-1409-x"],["dc.identifier.pmid","30610382"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16029"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59857"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/242209/EU//BIOSTAT-CHF"],["dc.relation.issn","1861-0692"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2105"],["dc.bibliographiccitation.issue","27"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","2114"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Filippatos, Gerasimos S."],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Boehm, Michael"],["dc.contributor.author","Gheorghiade, Mihai"],["dc.contributor.author","Kober, Lars"],["dc.contributor.author","Krum, Henry"],["dc.contributor.author","Maggioni, Aldo P."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Voors, Adriaan A."],["dc.contributor.author","Zannad, Faiez"],["dc.contributor.author","Kim, So-Young"],["dc.contributor.author","Nowack, Christina"],["dc.contributor.author","Palombo, Giovanni"],["dc.contributor.author","Kolkhof, Peter"],["dc.contributor.author","Kimmeskamp-Kirschbaum, Nina"],["dc.contributor.author","Pieper, Alexander"],["dc.contributor.author","Pitt, Bertram"],["dc.date.accessioned","2018-11-07T10:11:36Z"],["dc.date.available","2018-11-07T10:11:36Z"],["dc.date.issued","2016"],["dc.description.abstract","Aims To evaluate oral doses of the non-steroidal mineralocorticoid receptor antagonist finerenone given for 90 days in patients with worsening heart failure and reduced ejection fraction and chronic kidney disease and/or diabetes mellitus. Methods and results Miner Alocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF) was a randomized, double-blind, phase 2b multicentre study (ClinicalTrials.gov: NCT01807221). Of 1286 screened patients, 1066 were randomized. Patients received oral, once-daily finerenone (2.5, 5, 7.5, 10, or 15 mg, uptitrated to 5, 10, 15, 20, or 20 mg, respectively, on Day 30) or eplerenone (25 mg every other day, increased to 25 mg once daily on Day 30, and to 50 mg once daily on Day 60) for 90 days. The primary endpoint was the percentage of individuals with a decrease of >30% in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to Day 90. A key exploratory endpoint was a composite clinical endpoint of death from any cause, cardiovascular hospitalizations, or emergency presentation for worsening HF until Day 90. Mean age ranged from 69.2 to 72.5 years in different treatment groups (standard deviation 9.7-10.6 years). Decreases in NT-proBNP of >30% from baseline occurred in 37.2% of patients in the eplerenone group and 30.9, 32.5, 37.3, 38.8, and 34.2% in the 2.5 -> 5, 5 -> 10, 7.5 -> 15, 10 -> 20, and 15 -> 20 mg finerenone groups, respectively (P = 0.42-0.88). Except for the 2.5 -> 5 mg finerenone group, the composite clinical endpoint occurred numerically less frequently in finerenone-treated patients compared with eplerenone; this difference reached nominal statistical significance in the 10 -> 20 mg group (hazard ratio 0.56, 95% confidence interval, CI, 0.35; 0.90; nominal P = 0.02), despite the fact that this phase 2 study was not designed to detect statistical significant differences. A potassium level increase to >= 5.6 mmol/L at any time point occurred in 4.3% of patients, with a balanced distribution among all treatment groups. Conclusion Finerenone was well tolerated and induced a 30% or greater decrease in NT-proBNP levels in a similar proportion of patients to eplerenone. The finding of reduced clinical events in the finerenone 10 -> 20 mg group should be further explored in a large outcomes trial."],["dc.description.sponsorship","Bayer Pharma AG"],["dc.identifier.doi","10.1093/eurheartj/ehw132"],["dc.identifier.isi","000380177200010"],["dc.identifier.pmid","27130705"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14156"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40081"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.relation.issn","1522-9645"],["dc.relation.issn","0195-668X"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e113447"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","PloS one"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Graham, Susan"],["dc.contributor.author","Ye, Siqin"],["dc.contributor.author","Qian, Min"],["dc.contributor.author","Sanford, Alexandra R."],["dc.contributor.author","Di Tullio, Marco R."],["dc.contributor.author","Sacco, Ralph L."],["dc.contributor.author","Mann, Douglas L."],["dc.contributor.author","Levin, Bruce"],["dc.contributor.author","Pullicino, Patrick M."],["dc.contributor.author","Freudenberger, Ronald S."],["dc.contributor.author","Teerlink, John R."],["dc.contributor.author","Mohr, J. P."],["dc.contributor.author","Labovitz, Arthur J."],["dc.contributor.author","Lip, Gregory Y. H."],["dc.contributor.author","Estol, Conrado J."],["dc.contributor.author","Lok, Dirk J."],["dc.contributor.author","Ponikowski, Piotr"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Thompson, John L. P."],["dc.contributor.author","Homma, Shunichi"],["dc.date.accessioned","2019-07-09T11:40:43Z"],["dc.date.available","2019-07-09T11:40:43Z"],["dc.date.issued","2014"],["dc.description.abstract","We sought to determine whether cognitive function in stable outpatients with heart failure (HF) is affected by HF severity. A retrospective, cross-sectional analysis was performed using data from 2, 043 outpatients with systolic HF and without prior stroke enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. Multivariable regression analysis was used to assess the relationship between cognitive function measured using the Mini-Mental Status Exam (MMSE) and markers of HF severity (left ventricular ejection fraction [LVEF], New York Heart Association [NYHA] functional class, and 6-minute walk distance). The mean (SD) for the MMSE was 28.6 (2.0), with 64 (3.1%) of the 2,043 patients meeting the cut-off of MMSE <24 that indicates need for further evaluation of cognitive impairment. After adjustment for demographic and clinical covariates, 6-minute walk distance (β-coefficient 0.002, p<0.0001), but not LVEF or NYHA functional class, was independently associated with the MMSE as a continuous measure. Age, education, smoking status, body mass index, and hemoglobin level were also independently associated with the MMSE. In conclusion, six-minute walk distance, but not LVEF or NYHA functional class, was an important predictor of cognitive function in ambulatory patients with systolic heart failure."],["dc.format.extent","16"],["dc.identifier.doi","10.1371/journal.pone.0113447"],["dc.identifier.fs","608381"],["dc.identifier.pmid","25426862"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11221"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58233"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]